<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Trial &#8211; Our Story Insight</title>
	<atom:link href="https://www.ourstoryinsight.com/tag/trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.ourstoryinsight.com</link>
	<description>Product that tells our story</description>
	<lastBuildDate>Wed, 25 Mar 2026 05:20:50 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.ourstoryinsight.com/wp-content/uploads/2021/10/Capture-removebg-preview-22-e1635416645194-150x150.png</url>
	<title>Trial &#8211; Our Story Insight</title>
	<link>https://www.ourstoryinsight.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Jury in landmark Meta, Google addiction trial having difficulty coming to consensus</title>
		<link>https://www.ourstoryinsight.com/jury-in-landmark-meta-google-addiction-trial-having-difficulty-coming-to-consensus/</link>
					<comments>https://www.ourstoryinsight.com/jury-in-landmark-meta-google-addiction-trial-having-difficulty-coming-to-consensus/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Tue, 24 Mar 2026 10:02:52 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[addiction]]></category>
		<category><![CDATA[coming]]></category>
		<category><![CDATA[consensus]]></category>
		<category><![CDATA[difficulty]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[jury]]></category>
		<category><![CDATA[landmark]]></category>
		<category><![CDATA[Meta]]></category>
		<category><![CDATA[Trial]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=14138</guid>

					<description><![CDATA[<p>The jury in the social media addiction trial in Los Angeles told the judge on Monday it is having difficulty coming to a consensus with one defendant. The defendants are Google and Meta, but the jury did not specify which one it was referring to. Judge Carolyn B. Kuhl said the jury should reach a verdict [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/jury-in-landmark-meta-google-addiction-trial-having-difficulty-coming-to-consensus/">Jury in landmark Meta, Google addiction trial having difficulty coming to consensus</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The jury in the social media addiction trial in Los Angeles told the judge on Monday it is having difficulty coming to a consensus with one defendant.</p>
<p>The defendants are Google and Meta, but the jury did not specify which one it was referring to.</p>
<p>Judge Carolyn B. Kuhl said the jury should reach a verdict if it can, adding that the case will have to be retried with a new set of jurors if it cannot reach an agreement.</p>
<p>Meta CEO Mark Zuckerberg testified last month. <span class="credit">Getty Images</span></p>
<p>The jury has been deliberating for over a week in a trial that involves a young woman who said she became addicted to Google’s YouTube and Meta’s Instagram at a young age. <span class="credit">AFP via Getty Images</span></p>
<p>The jury has been deliberating for over a week in a trial that involves a young woman who said she became addicted to Google’s YouTube and Meta’s Instagram at a young age.</p>
<p>The outcome of her case could influence thousands of similar cases against the tech companies brought by parents, attorneys general and school districts.</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/jury-in-landmark-meta-google-addiction-trial-having-difficulty-coming-to-consensus/">Jury in landmark Meta, Google addiction trial having difficulty coming to consensus</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/jury-in-landmark-meta-google-addiction-trial-having-difficulty-coming-to-consensus/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Meta delays release of new AI, weighs licensing Google&#8217;s Gemini after disappointing trial runs: report</title>
		<link>https://www.ourstoryinsight.com/meta-delays-release-of-new-ai-weighs-licensing-googles-gemini-after-disappointing-trial-runs-report/</link>
					<comments>https://www.ourstoryinsight.com/meta-delays-release-of-new-ai-weighs-licensing-googles-gemini-after-disappointing-trial-runs-report/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Fri, 13 Mar 2026 21:11:06 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[delays]]></category>
		<category><![CDATA[disappointing]]></category>
		<category><![CDATA[Gemini]]></category>
		<category><![CDATA[Googles]]></category>
		<category><![CDATA[Meta]]></category>
		<category><![CDATA[Release]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[runs]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[weighslicensing]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=13881</guid>

					<description><![CDATA[<p>Mark Zuckerberg’s Meta is reportedly delaying the release of its next artificial intelligence model at least about two months after internal tests showed the tech falling short of rival models from Google, OpenAI and Anthropic. The leaders of Meta’s AI division are considering temporarily licensing Google’s Gemini to power its products in the wake of [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/meta-delays-release-of-new-ai-weighs-licensing-googles-gemini-after-disappointing-trial-runs-report/">Meta delays release of new AI, weighs licensing Google&#8217;s Gemini after disappointing trial runs: report</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Mark Zuckerberg’s Meta is reportedly delaying the release of its next artificial intelligence model at least about two months after internal tests showed the tech falling short of rival models from Google, OpenAI and Anthropic.</p>
<p>The leaders of Meta’s AI division are considering temporarily licensing Google’s Gemini to power its products in the wake of the lackluster results, the New York Times reported this week.</p>
<p>Internal Meta testing showed lackluster performance for its new “Avocado” AI model even after techies worked on it for months, anonymous sources told the Times.</p>
<p>Mark Zuckerberg is delaying the release of Meta’s next artificial intelligence model. <span class="credit">Getty Images</span></p>
<p>Instead of rolling out this month, Avocado is reportedly expected to launch around May after it failed to measure up in terms of reasoning, coding and writing.</p>
<p>The setbacks come after Zuckerberg, 41, threw the kitchen sink at developing AI. Meta has spent billions hiring top AI talent and committed $600 billion to building data centers to power the tech. Meta projected in January it would spend as much as $135 billion this year alone — nearly twice the $72 billion it blew through last year developing AI.</p>
<p>Zuckerberg said in July that Meta’s new AI models would “push the frontier in the next year or so.”</p>
<p>The Times noted that Avocado outperformed Meta’s previous AI model and did better than Google’s Gemini 2.5 from March — but lagged behind Gemini 3.0 from November.</p>
<p>“I expect our first models will be good, but more importantly will show the rapid trajectory we’re on,” Zuckerberg said on an investor call in January.</p>
<p>Alexandr Wang, Meta’s chief AI officer.  <span class="credit">AFP via Getty Images</span></p>
<p>A Meta spokesperson said: “We’ll steadily push the frontier over the course of the year as we continue to release new models. We’re excited for people to see what we’ve been cooking very soon.”</p>
<p>AI efforts by Meta, the owner of Facebook, Instagram and Threads, are being closely watched in the artificial intelligence arms race. Google, OpenAI and Anthropic are widely regarded as ahead in developing foundational AI models — the underlying technology for chatbots, video generators and coding tools. </p>
<h3 class="inline-module__title headline headline--combo-sm-md">
							Start your day with all you need to know						</h3>
<p class="inline-module__cta">
							Morning Report delivers the latest news, videos, photos and more.						</p>
<p><h3 class="inline-module__title headline headline--combo-sm-md">
						Thanks for signing up!					</h3>
</p>
<p>Zuckerberg kicked his AI effort into overdrive after Meta’s previous model, Llama 4, fell short of expectations last year. To catch up, the company invested $14.3 billion in the startup Scale AI in June and made its 29-year-old chief executive, Alexandr Wang, its new chief AI officer.  </p>
<p>Wang helped assemble an AI lab within Meta called TBD Lab. The unit finished the first stage of Avocado’s development, called “pre-training,” at the end of last year, according to the Times. In January, it began the next phase, “post-training,” and set a target release date of mid-March.</p>
<p>Meta had been working on the new AI model, called Avocado, for months. <span class="credit">dpa/picture alliance via Getty Images</span></p>
<p>The only product Wang’s AI division has released so far is Vibes, an AI video app similar to OpenAI’s Sora.</p>
<p>TBD Lab, which has around 100 employees, has seen some turnover, with a handful of researchers departing before Avocado’s release, according to the report.</p>
<p>Meta’s top brass have reportedly debated whether or not its new AI model will be “open source,” meaning parts of its code would be available to other developers.</p>
<p>Chris Cox, Meta’s chief product officer. <span class="credit">Bloomberg via Getty Images</span></p>
<p>Meta has long championed open source models, arguing that they help advance tech, while companies like OpenAI and Anthropic have said letting others build off their AI would pose safety risks.</p>
<p>The Times article detailed tensions between Wang and Chris Cox, Meta’s chief product officer, and Andrew Bosworth, the chief technology officer. Disagreements reportedly centered on how new AI models should improve Meta’s ad business.</p>
<p>Meta wrote in a note to employees last week, which was reported earlier by the Wall Street Journal, that it would create an AI team under Bosworth that would work with Wang.</p>
<p>Last week, Meta told employees it was creating an AI team under Bosworth that would work with Wang, according to the Wall Street Journal.</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/meta-delays-release-of-new-ai-weighs-licensing-googles-gemini-after-disappointing-trial-runs-report/">Meta delays release of new AI, weighs licensing Google&#8217;s Gemini after disappointing trial runs: report</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/meta-delays-release-of-new-ai-weighs-licensing-googles-gemini-after-disappointing-trial-runs-report/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Elon Musk to testify securities fraud trial over Twitter deal in SF</title>
		<link>https://www.ourstoryinsight.com/elon-musk-to-testify-securities-fraud-trial-over-twitter-deal-in-sf/</link>
					<comments>https://www.ourstoryinsight.com/elon-musk-to-testify-securities-fraud-trial-over-twitter-deal-in-sf/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Wed, 04 Mar 2026 13:35:10 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[Elon]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[Musk]]></category>
		<category><![CDATA[Securities]]></category>
		<category><![CDATA[testify]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Twitter]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=13683</guid>

					<description><![CDATA[<p>Elon Musk looks on as President Donald Trump speaks at the US-Saudi Investment Forum at the John F. Kennedy Center for the Performing Arts in Washington, Nov. 19, 2025. Brendan Smialowski &#124; Afp &#124; Getty Images Since buying Twitter for around $44 billion in late 2022, Elon Musk has changed the name to X, merged [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/elon-musk-to-testify-securities-fraud-trial-over-twitter-deal-in-sf/">Elon Musk to testify securities fraud trial over Twitter deal in SF</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="HighlightShare-hidden" style="top:0;left:0"/></p>
<p>Elon Musk looks on as President Donald Trump speaks at the US-Saudi Investment Forum at the John F. Kennedy Center for the Performing Arts in Washington, Nov. 19, 2025.</p>
<p>Brendan Smialowski | Afp | Getty Images</p>
<p>Since buying Twitter for around $44 billion in late 2022, Elon Musk has changed the name to X, merged the social media platform with artificial intelligence startup xAI and then combined that company with his defense contractor, SpaceX. </p>
<p>Musk&#8217;s next big step may be to take SpaceX public in what would likely be a record IPO. But first, he has to revisit his past. </p>
<p>On Wednesday, Musk is expected to appear at a federal courthouse in San Francisco to defend himself against allegations that he committed civil securities fraud in the run-up to his purchase of Twitter. </p>
<p>Investors in Twitter filed a class action suit against Musk in October 2022 when — after months of tension and flip-flopping — he finally agreed to buy the social network for $54.20 a share, the price he originally promised in April of that year.</p>
<p>The investors alleged that Musk, now the world&#8217;s richest person, engaged in a scheme to weigh down Twitter&#8217;s stock in order to pressure the board to sell to him for a lower price. Musk&#8217;s attorneys have argued that he never intended to hurt Twitter or its other investors.</p>
<p>A defeat at trial could result in Musk being forced to pay former Twitter investors to make up for their reported losses, and could influence the outcomes in related lawsuits down the line. </p>
<p>The SEC has separately accused Musk of violating financial regulations by failing to disclose his active stake in Twitter as he was preparing to take over the company within a legally required time frame. His offer for Twitter landed a little over a week after Musk revealed a 9.1% stake in the company. </p>
<p>After his bid, Musk used his widely followed account on Twitter, as well as press interviews, to complain about bots, spam and fake accounts on the social network. He also said he would put the deal on hold until the company&#8217;s board satisfied demands for more comprehensive internal data than he had previously requested.</p>
<p>Twitter shares dropped after it appeared Musk may back out of the buyout. Investors in the class action claim they sold prematurely at prices below the $54.20 acquisition price because they thought the deal was unraveling. </p>
<p>In another lawsuit, Twitter sued Musk in the Delaware Court of Chancery to force him to complete the deal at the price he originally put forward. Musk settled the Delaware suit, buying Twitter and setting the stage for the consolidation of X, xAI and SpaceX, which also owns Starlink, into an entity now valued by private investors at $1.25 trillion. </p>
<p><strong>WATCH:</strong> SpaceX IPO will reprice the entire private space market</p>
<p><span class="InlineVideo-videoButton"/><span/></p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/elon-musk-to-testify-securities-fraud-trial-over-twitter-deal-in-sf/">Elon Musk to testify securities fraud trial over Twitter deal in SF</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/elon-musk-to-testify-securities-fraud-trial-over-twitter-deal-in-sf/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Uber ordered to pay woman $8.5M in first trial over driver sex assault claims</title>
		<link>https://www.ourstoryinsight.com/uber-ordered-to-pay-woman-8-5m-in-first-trial-over-driver-sex-assault-claims/</link>
					<comments>https://www.ourstoryinsight.com/uber-ordered-to-pay-woman-8-5m-in-first-trial-over-driver-sex-assault-claims/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Fri, 06 Feb 2026 04:36:52 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[85M]]></category>
		<category><![CDATA[assault]]></category>
		<category><![CDATA[claims]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[ordered]]></category>
		<category><![CDATA[pay]]></category>
		<category><![CDATA[sex]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[über]]></category>
		<category><![CDATA[woman]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=13021</guid>

					<description><![CDATA[<p>A federal jury in Phoenix ordered Uber on Thursday to pay $8.5 million after finding it liable in a lawsuit brought by a woman who said she was sexually assaulted by a driver, a verdict that could influence thousands of similar cases against the ride-hailing company. The case, brought by plaintiff Jaylynn Dean, was the first trial – [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/uber-ordered-to-pay-woman-8-5m-in-first-trial-over-driver-sex-assault-claims/">Uber ordered to pay woman $8.5M in first trial over driver sex assault claims</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A federal jury in Phoenix ordered Uber on Thursday to pay $8.5 million after finding it liable in a lawsuit brought by a woman who said she was sexually assaulted by a driver, a verdict that could influence thousands of similar cases against the ride-hailing company.</p>
<p>The case, brought by plaintiff Jaylynn Dean, was the first trial – known as a “bellwether” – of more than 3,000 similar lawsuits against Uber that have been consolidated in federal court. Bellwether trials are used to test legal theories and help gauge the value of claims for possible settlements.</p>
<p>The jury found that the driver was an agent of Uber, so the company was responsible for his actions. They awarded Dean $8.5 million in compensatory damages but declined to award punitive damages. Attorneys for Dean had sought more than $140 million in damages.</p>
<p>The case, brought by plaintiff Jaylynn Dean, was the first trial – known as a “bellwether” – of more than 3,000 similar lawsuits against Uber that have been consolidated in federal court.  <span class="credit">REUTERS</span></p>
<p>In a statement, an Uber spokesperson noted that the jury rejected Dean’s other claims, that the company was negligent or that its safety systems were defective, adding that the company plans to appeal. “This verdict affirms that Uber acted responsibly and has invested meaningfully in rider safety,” the spokesperson said.</p>
<p>Sarah London, an attorney for Dean, said the verdict “validates the thousands of survivors who have come forward at great personal risk to demand accountability against Uber for its focus on profit over passenger safety.”</p>
<p>Uber shares fell 0.5% in extended trading following announcement of the verdict.</p>
<p>Dean, an Oklahoma resident, sued Uber in 2023, one month after her alleged assault in Arizona. She said Uber was aware of a wave of sexual assaults committed by its drivers, but had failed to take basic actions to improve the safety of its riders. Such assertions have long dogged the company, drawing headlines and congressional scrutiny.</p>
<p>Alexandra Walsh, an attorney for Dean, said during the trial’s closing arguments that Uber had marketed itself as a safe option for women traveling at night, particularly if they had been drinking.</p>
<p>An Uber spokesperson noted that the jury rejected Dean’s other claims, that the company was negligent or that its safety systems were defective, adding that the company plans to appeal. CEO Dara Khosrowshahi, above. <span class="credit">Getty Images</span></p>
<p>“Women know it’s a dangerous world. We know about the risk of sexual assault,” Walsh said. “They made us believe that this was a place that was safe from that.”</p>
<h2 class="wp-block-heading">Uber says not responsible for driver actions</h2>
<p>Uber, which has faced numerous safety controversies, including allegations of lax driver vetting and a culture critics said prioritized growth over passenger protection, has argued that it should not be held liable for criminal conduct by drivers who use its platform, saying that its background checks and disclosures about assaults are sufficient.</p>
<p>Uber has argued that it should not be held liable for criminal conduct by drivers who use its platform, saying that its background checks and disclosures about assaults are sufficient. <span class="credit">Diego – stock.adobe.com</span></p>
<p>The company maintains that its drivers are independent contractors rather than employees, and that regardless of their classification it cannot be responsible for actions that fall outside the scope of what could reasonably be considered their duties.</p>
<p>“He had no criminal history. None,” Kim Bueno, an attorney for Uber, said of the driver during closing arguments, noting that he had 10,000 trips on the app and a nearly perfect rating from riders. “Was this foreseeable to Uber? And the answer to that has to be no.”</p>
<h3 class="inline-module__title headline headline--combo-sm-md">
							Start your day with all you need to know						</h3>
<p class="inline-module__cta">
							Morning Report delivers the latest news, videos, photos and more.						</p>
<p><h3 class="inline-module__title headline headline--combo-sm-md">
						Thanks for signing up!					</h3>
</p>
<p>Dean’s lawsuit said she was intoxicated when she hired an Uber driver to take her from her boyfriend’s home to her hotel.</p>
<p>The driver asked her harassing questions on the ride before stopping the car and raping her, Dean alleged in the lawsuit.</p>
<p>Uber is also facing more than 500 cases in California state court. Rival Lyft is facing similar lawsuits in both state and federal court, <span class="credit">Tada Images – stock.adobe.com</span></p>
<p>US District Judge Charles Breyer, who normally sits on the bench in San Francisco, oversaw Dean’s case in Phoenix. Breyer is managing all of the similar federal cases against Uber, which have been centralized in his court in San Francisco.</p>
<p>The company is also facing more than 500 cases in California state court. In the only one of those cases to go to trial so far, a jury in September sided with Uber. The jury found that while the company had been negligent with its safety measures, that negligence was not a substantial factor in causing the woman’s harm.</p>
<p>Uber rival Lyft is facing similar lawsuits in both state and federal court, although there is no coordinated federal litigation for those claims. Shares of Lyft were down 1% after the verdict.</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/uber-ordered-to-pay-woman-8-5m-in-first-trial-over-driver-sex-assault-claims/">Uber ordered to pay woman $8.5M in first trial over driver sex assault claims</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/uber-ordered-to-pay-woman-8-5m-in-first-trial-over-driver-sex-assault-claims/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Elon Musk&#8217;s lawsuit against ChatGPT owner OpenAI can head to trial</title>
		<link>https://www.ourstoryinsight.com/elon-musks-lawsuit-against-chatgpt-owner-openai-can-head-to-trial/</link>
					<comments>https://www.ourstoryinsight.com/elon-musks-lawsuit-against-chatgpt-owner-openai-can-head-to-trial/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 08 Jan 2026 12:47:05 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[ChatGPT]]></category>
		<category><![CDATA[Elon]]></category>
		<category><![CDATA[Lawsuit]]></category>
		<category><![CDATA[Musks]]></category>
		<category><![CDATA[OpenAI]]></category>
		<category><![CDATA[owner]]></category>
		<category><![CDATA[Trial]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=12150</guid>

					<description><![CDATA[<p>Billionaire entrepreneur Elon Musk persuaded a judge on Wednesday to allow a jury trial on his allegations that ChatGPT maker OpenAI violated its founding mission in its high-profile restructuring to a for-profit entity. Musk was a cofounder of OpenAI in 2015 but left in 2018 and now runs an AI company that competes with it. US District Judge Yvonne [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/elon-musks-lawsuit-against-chatgpt-owner-openai-can-head-to-trial/">Elon Musk&#8217;s lawsuit against ChatGPT owner OpenAI can head to trial</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Billionaire entrepreneur Elon Musk persuaded a judge on Wednesday to allow a jury trial on his allegations that ChatGPT maker OpenAI violated its founding mission in its high-profile restructuring to a for-profit entity.</p>
<p>Musk was a cofounder of OpenAI in 2015 but left in 2018 and now runs an AI company that competes with it.</p>
<p>US District Judge Yvonne Gonzalez Rogers in Oakland, Calif., said at a hearing that there was “plenty of evidence” suggesting OpenAI’s leaders made assurances that its original nonprofit structure was going to be maintained.</p>
<p>Billionaire entrepreneur Elon Musk persuaded a judge  to allow a jury trial on his allegations that ChatGPT maker OpenAI violated its founding mission in its high-profile restructuring to a for-profit entity. <span class="credit">REUTERS</span></p>
<p>The judge said there were enough disputed facts to let a jury consider the claims at a trial scheduled for March, rather than decide the issues herself. She said she would issue a written order after the hearing that addresses OpenAI’s bid to throw out the case.</p>
<p>The court battle comes amid a broader showdown over dominance in the market for generative artificial intelligence. Musk’s xAI and its chatbot Grok are competing with OpenAI and other technology developers.</p>
<p>Musk is seeking unspecified monetary damages from what he calls “ill-gotten gains” by OpenAI.</p>
<p>OpenAI and Musk’s artificial intelligence startup xAI did not immediately respond to requests for comment.</p>
<p>Musk contends he contributed about $38 million — roughly 60% of OpenAI’s early funding — along with strategic guidance and credibility, based on assurances that the organization would remain a nonprofit dedicated to the public benefit.</p>
<p>The lawsuit accuses OpenAI co-founders Sam Altman (above) and Greg Brockman of plotting a for-profit switch to enrich themselves. <span class="credit">REUTERS</span></p>
<p>The lawsuit accuses OpenAI co-founders Sam Altman and Greg Brockman of plotting a for-profit switch to enrich themselves, culminating in multibillion-dollar deals with Microsoft and a recent restructuring.</p>
<p>OpenAI, Altman and Brockman have denied the claims, and they called Musk “a frustrated commercial competitor seeking to slow down a mission-driven market leader.”</p>
<p>Microsoft, which is also a defendant, urged Gonzalez Rogers to toss Musk’s claims against it. Above, Microsoft CEO Satya Nadella with Altman in 2023. <span class="credit">Getty Images</span></p>
<p>Microsoft, which is also a defendant, urged Gonzalez Rogers to toss Musk’s claims against it. A lawyer for Microsoft said there was no evidence that the company “aided and abetted” OpenAI.</p>
<p>Microsoft did not immediately respond to a request for comment.</p>
<h3 class="inline-module__title headline headline--combo-sm-md">
							Start your day with all you need to know						</h3>
<p class="inline-module__cta">
							Morning Report delivers the latest news, videos, photos and more.						</p>
<p><h3 class="inline-module__title headline headline--combo-sm-md">
						Thanks for signing up!					</h3>
</p>
<p>Lawyers for OpenAI at the hearing asked Gonzalez Rogers to enter judgment against Musk, contending that he had not shown enough of a factual basis to sustain his allegations including fraud and breach of contract.</p>
<p>OpenAI also contends that Musk failed to bring his allegations in a timely manner. Gonzalez Rogers said the jury would be asked to weigh whether the lawsuit was filed outside the statute of limitations.</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/elon-musks-lawsuit-against-chatgpt-owner-openai-can-head-to-trial/">Elon Musk&#8217;s lawsuit against ChatGPT owner OpenAI can head to trial</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/elon-musks-lawsuit-against-chatgpt-owner-openai-can-head-to-trial/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>TikTok must face trial on kids exploitation lawsuit</title>
		<link>https://www.ourstoryinsight.com/tiktok-must-face-trial-on-kids-exploitation-lawsuit/</link>
					<comments>https://www.ourstoryinsight.com/tiktok-must-face-trial-on-kids-exploitation-lawsuit/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Sun, 13 Jul 2025 11:45:15 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[exploitation]]></category>
		<category><![CDATA[face]]></category>
		<category><![CDATA[kids]]></category>
		<category><![CDATA[Lawsuit]]></category>
		<category><![CDATA[TikTok]]></category>
		<category><![CDATA[Trial]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=8170</guid>

					<description><![CDATA[<p>The TikTok logo is seen in this illustration taken on Aug. 22, 2022. Dado Ruvic &#124; Reuters A judge this week rejected TikTok&#8217;s attempt to dismiss a lawsuit by the state of New Hampshire accusing it of using manipulative design features aimed at children and teens. &#8220;The Court&#8217;s decision is an important step toward holding [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/tiktok-must-face-trial-on-kids-exploitation-lawsuit/">TikTok must face trial on kids exploitation lawsuit</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="HighlightShare-hidden" style="top:0;left:0"/></p>
<p>The TikTok logo is seen in this illustration taken on Aug. 22, 2022.</p>
<p>Dado Ruvic | Reuters</p>
<p>A judge this week rejected TikTok&#8217;s attempt to dismiss a lawsuit by the state of New Hampshire accusing it of using manipulative design features aimed at children and teens.</p>
<p>&#8220;The Court&#8217;s decision is an important step toward holding TikTok accountable for unlawful practices that put children at risk,&#8221; state Attorney General John Formella said in a statement Friday.</p>
<p>In his ruling Tuesday, New Hampshire Superior Court Judge John Kissinger Jr. said the state&#8217;s allegations were valid and specific enough to proceed, writing the civil claims were &#8220;based on the App&#8217;s alleged defective and dangerous features&#8221; and not the content in the app.</p>
<p>The state alleges that social media platform TikTok is intentionally designed to be addictive and aims to exploit its young user base.</p>
<p>The suit accuses the platform of implementing &#8220;addictive design features&#8221; meant to keep children engaged longer, increasing their exposure to advertisements and prompting purchases through TikTok&#8217;s e-commerce platform TikTok Shop.</p>
<p>A TikTok spokesperson said in a statement Friday that the suit &#8220;presents outdated and cherry-picked claims.&#8221;</p>
<p>&#8220;We continue to provide robust safety protections and screen time limits for teen accounts enabled by default, Family Pairing tools for parents to supervise their teens, strict livestreaming requirements, and proactive ongoing enforcement of our Community Guidelines,&#8221; the spokesperson said.</p>
<p>The case is the latest example of attorneys general targeting design elements and safety policies from tech companies instead of the content on the platforms, which is created by other users.</p>
<p>Meta was accused by several states of implementing addictive features across its family of apps that have detrimental effects on children&#8217;s mental health.</p>
<p>New Mexico filed a lawsuit against <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-6">Snapchat<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> in September, alleging the app was creating an environment where &#8220;predators can easily target children through sextortion schemes.&#8221;</p>
<p>In April, social-messaging platform Discord was sued by the New Jersey attorney general over misleading consumers about child safety features.</p>
<p>Congress has attempted to take action on regulating social media platforms, but to no avail. The Kids Online Safety Act was reintroduced to Congress in May after stalling in 2024.</p>
<p>The measure would require social media platforms to have a &#8220;duty of care&#8221; to prevent their products from harming children.</p>
<p>TikTok&#8217;s latest legal hurdle comes as its future in the U.S. remains uncertain.</p>
<p>In April 2024, former President Joe Biden signed a law requiring ByteDance to divest of TikTok or see the app banned in the U.S. The app was removed from <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-13">Apple<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> and <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-14">Google<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> app stores in January ahead of President Donald Trump&#8217;s inauguration.</p>
<p>Since taking office, Trump has postponed enforcement of the ban and continued to push back deadlines.</p>
<p>In June, Trump granted ByteDance more time to sell off its U.S. TikTok operations, marking his third extension. The updated deadline is now set for Sept. 17.</p>
<p>Trump also said in June that a group of &#8220;very wealthy people&#8221; is ready to buy TikTok and told reporters that he would be having discussions with China about a potential deal.</p>
<p>TikTok is now building a new version of its app for U.S. users, according to The Information. The stand-alone app is expected to operate on a separate algorithm and data system, Reuters said.</p>
<p>TikTok refuted the Reuters report, calling it &#8220;factually inaccurate.&#8221;</p>
<h2 class="RelatedContent-header">Don’t miss these insights from CNBC PRO</h2>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/tiktok-must-face-trial-on-kids-exploitation-lawsuit/">TikTok must face trial on kids exploitation lawsuit</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/tiktok-must-face-trial-on-kids-exploitation-lawsuit/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Lawyers urging &#8216;caution&#8217; on antitrust remedies in Google search trial have cozy ties to Big Tech</title>
		<link>https://www.ourstoryinsight.com/lawyers-urging-caution-on-antitrust-remedies-in-google-search-trial-have-cozy-ties-to-big-tech/</link>
					<comments>https://www.ourstoryinsight.com/lawyers-urging-caution-on-antitrust-remedies-in-google-search-trial-have-cozy-ties-to-big-tech/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Mon, 09 Jun 2025 10:14:30 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[antitrust]]></category>
		<category><![CDATA[Big]]></category>
		<category><![CDATA[caution]]></category>
		<category><![CDATA[Cozy]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[Lawyers]]></category>
		<category><![CDATA[remedies]]></category>
		<category><![CDATA[search]]></category>
		<category><![CDATA[tech]]></category>
		<category><![CDATA[ties]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[urging]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=7516</guid>

					<description><![CDATA[<p>A group of prominent lawyers claimed to be objective last month as they urged a federal judge to take “caution” when imposing antitrust remedies against Google’s online search empire — but many of them have cozy ties to Big Tech, The Post has learned. US District Judge Amit Mehta is expected to rule by August [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/lawyers-urging-caution-on-antitrust-remedies-in-google-search-trial-have-cozy-ties-to-big-tech/">Lawyers urging &#8216;caution&#8217; on antitrust remedies in Google search trial have cozy ties to Big Tech</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>A group of prominent lawyers claimed to be objective last month as they urged a federal judge to take “caution” when imposing antitrust remedies against Google’s online search empire — but many of them have cozy ties to Big Tech, The Post has learned.</p>
<p>US District Judge Amit Mehta is expected to rule by August on the best way to rein in Google’s illegal dominance over online search after ruling last year that the company was a “monopolist.” The Justice Department, rather than merely punishing past misdeeds, wants Google and CEO Sundar Pichai to sell the Chrome web browser, among other remedies.</p>
<p>On May 6, a group of former DOJ and Federal Trade Commission antitrust enforcers submitted an amicus brief warning the federal judge against aggressive remedies. The lawyers said their brief was made “in support of neither party” and was intended to guide Mehta on following the “proper remedy standard.”</p>
<p>However, many of brief’s coauthors have direct or indirect links to Google and other Big Tech firms. That includes Joe Sims, who last year dismissed criticism of Google’s widespread evidence destruction as “silly,” and Willard Tom, who once defended Google in the high-profile antitrust lawsuit filed by “Fortnite” maker Epic Games.</p>
<p>Their arguments closely match those of the defense offered by Google, which claims the DOJ’s proposals go far beyond the bounds of antitrust law and that the court risks jeopardizing American AI leadership – and even national security.</p>
<p>The lawyers’ links to Big Tech raised alarms with Google’s critics, including Sacha Haworth, executive director at the Tech Oversight Project, who told The Post that it “speaks volumes that the only people rushing to Google’s defense are people paid by Google to care.”</p>
<p>Google faces a potential breakup of its business in the search trial.  <span class="credit">AP</span></p>
<p>“If Google is broken up, it will be a win for our digital economy that will lead to lower prices and more choices for consumers,” Haworth added.</p>
<p>Aside from a forced divestment of Chrome, the DOJ wants Google to share its search data with rivals. The agency has also asked Mehta to consider the potential impact of Google’s massive investments in AI-powered search when crafting any remedies.</p>
<p>Elsewhere, the feds want Google to be barred from paying billions to companies like Apple to ensure its search engine is set as the default option on most smartphones. They also propose a forced divestiture of Google’s Android software if initial remedies prove ineffective.</p>
<p>Google, led by CEO Sundar Pichai, is fighting to avoid a forced divestiture of Chrome.  <span class="credit">Getty Images</span></p>
<p>“We’ve long said the DOJ’s proposals go miles beyond the Court’s decision,” a Google spokesperson said in a statement. “We appreciate that a wide range of experts, academics and businesses agree.”</p>
<p>An amicus brief – also known as a “friend of the court” brief – generally includes information that interested third parties want to flag for the judge’s consideration before reaching a verdict.</p>
<p>In a filing, the brief’s coauthors noted that they were not paid by any outside party and that no outside party had contributed to the writing.</p>
<p>Contributors included Tad Lipsky, who heads up the competition advocacy program at George Mason University’s Global Antitrust Institute – which has received millions in funding from Google and other Big Tech firms while frequently arguing for a light touch on antitrust enforcement.</p>
<p>Sims retired as a partner at law firm Jones Day in 2016. In July 2024, Jones Day successfully secured dismissal of a class-action suit accusing Google of antitrust violations tied to its Maps service.</p>
<p>Google faced criticism for destroying employee chat logs that it had been ordered to preserve. <span class="credit">REUTERS</span></p>
<p>Last August, Sims raised eyebrows when he argued that Mehta was “silly” for criticizing Google over its deletion of employee chat logs during the DOJ’s search trial – in violation of court orders to preserve evidence.</p>
<p>“No firm has an obligation to create a paper trail for people or entities that may want to attack it,” Sims wrote on X. “If anything, it has a fiduciary obligation to do just the opposite.”</p>
<p>Tom is a former partner at Morgan, Lewis &#038; Bockius who represented Google against “Fortnite” maker Epic Games’s antitrust lawsuit until his retirement in July 2022. Google eventually lost the suit in a bombshell ruling that has major implications for its “Google Play” app store.</p>
<p>Richard Parker previously represented Apple in the ebooks case bought the DOJ and currently works at Milbank Tweed, a firm that advised Google in the search trial and helped argue its ongoing appeal of the Epic Games verdict.</p>
<p>The brief notes that Parker contributed in “his personal capacity” and had “not worked for Google on this matter or any other matter.”</p>
<p>US District Judge Amit Mehta is pictured.  <span class="credit">AFP/Getty Images</span></p>
<p>Terry Calvani worked law firm Freshfields Bruckhaus Deringer from 2005 to 2019 – a period of time in which the firm served as an outside counsel for Google in several lawsuits. From 2020 to 2025, Calvini was a senior adviser at strategic communications firm Brunswick Group, which counts Google as a client.</p>
<p>Several enforcers who backed the amicus brief, including Sims and Lipsky, are listed as authors for Truth on the Market – a competition law-focused blog with close ties to the Big Tech-funded International Center for Law and Economics.</p>
<p>Jon Neuchterlein is a nonresident senior fellow at the Technology Policy Institute, which acknowledges on its website that it has received from donations from the likes of Google, Amazon, and Apple, among other tech firms.</p>
<p>Judge Mehta is expected to rule on potential remedies by August.  <span class="credit">U.S. District Court for the District of Columbia</span></p>
<p>From 2015 to 2024, Neuchterlein was a partner at the law firm Sidley Austin. During his tenure, the firm counted Amazon, Apple, Microsoft and Intel among its clients.</p>
<p>In their brief, the antitrust lawyers urged Mehta to take “caution” when considering two elements of the DOJ’s proposal – the forced Chrome divestiture and the search data-sharing requirement – to avoid overstepping the bounds of antitrust law.</p>
<p>“Antitrust remedies in a monopoly maintenance case are intended to terminate the unlawful conduct and prevent its recurrence, and remediate proven harm to competition caused by the illegal conduct,” the brief said.</p>
<p>The lawyers added that remedies that “further than that or that are not narrowly designed to achieve those goals can undermine the purpose of the antitrust laws by inhibiting the very robust competition that those laws are intended to promote.”</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/lawyers-urging-caution-on-antitrust-remedies-in-google-search-trial-have-cozy-ties-to-big-tech/">Lawyers urging &#8216;caution&#8217; on antitrust remedies in Google search trial have cozy ties to Big Tech</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/lawyers-urging-caution-on-antitrust-remedies-in-google-search-trial-have-cozy-ties-to-big-tech/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Meta’s Antitrust Trial Begins as FTC Argues Company Built Social Media Monopoly</title>
		<link>https://www.ourstoryinsight.com/metas-antitrust-trial-begins-as-ftc-argues-company-built-social-media-monopoly/</link>
					<comments>https://www.ourstoryinsight.com/metas-antitrust-trial-begins-as-ftc-argues-company-built-social-media-monopoly/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Mon, 14 Apr 2025 20:29:31 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[antitrust]]></category>
		<category><![CDATA[Argues]]></category>
		<category><![CDATA[begins]]></category>
		<category><![CDATA[built]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[FTC]]></category>
		<category><![CDATA[media]]></category>
		<category><![CDATA[Metas]]></category>
		<category><![CDATA[Monopoly]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Trial]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=6437</guid>

					<description><![CDATA[<p>The Federal Trade Commission on Monday accused Meta of creating a monopoly that squelched competition by buying start-ups that stood in its way, kicking off a landmark antitrust trial that could dismantle a social media empire that has transformed how the world connects online. In a packed courtroom in the U.S. District Court of the [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/metas-antitrust-trial-begins-as-ftc-argues-company-built-social-media-monopoly/">Meta’s Antitrust Trial Begins as FTC Argues Company Built Social Media Monopoly</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p></p>
<p class="css-at9mc1 evys1bk0">The Federal Trade Commission on Monday accused Meta of creating a monopoly that squelched competition by buying start-ups that stood in its way, kicking off a landmark antitrust trial that could dismantle a social media empire that has transformed how the world connects online.</p>
<p class="css-at9mc1 evys1bk0">In a packed courtroom in the U.S. District Court of the District of Columbia, the F.T.C. opened its first antitrust trial under the Trump administration by arguing that Meta illegally cemented a monopoly in social networking by acquiring Instagram and WhatsApp when they were tiny start-ups. Those actions were part of a “buy-or-bury strategy,” the F.T.C. said.</p>
<p class="css-at9mc1 evys1bk0">Ultimately, the purchases coalesced Meta’s power, depriving consumers of other social networking options and edging out competition, the government said.</p>
<p class="css-at9mc1 evys1bk0">“For more than 100 years, American public policy has insisted firms must compete if they want to succeed,&#8221; said Daniel Matheson, the F.T.C.’s lead litigator in the case, in his opening remarks. “The reason we are here is that Meta broke the deal.”</p>
<p class="css-at9mc1 evys1bk0">“They decided that competition was too hard and it would be easier to buy out their rivals than to compete with them,” he added.</p>
<p class="css-at9mc1 evys1bk0">Meta’s lawyers denied the allegations in opening arguments, countering that the company faces plenty of competition from TikTok and other social media platforms. The F.T.C. approved the acquisitions of Instagram and WhatsApp more than a decade ago, and it would set a dangerous precedent for the business world to try to unwind the mergers, the lawyers added.</p>
<p class="css-at9mc1 evys1bk0">“This case is a grab bag of F.T.C. theories at war with fact and at war with the law,” said Mark Hansen, the company’s litigator and a partner at the law firm Kellogg, Hansen, Todd, Figel &#038; Frederick. “The facts are going to prove that the F.T.C.’s theories are all wrong.”</p>
<p class="css-at9mc1 evys1bk0">The trial — Federal Trade Commission v. Meta Platforms — poses the most consequential threat to the business empire of Mark Zuckerberg, the company’s co-founder. If the government succeeds, the F.T.C. would most likely ask Meta to divest Instagram and WhatsApp, potentially shifting the way that Silicon Valley does business and altering a long pattern of big tech companies snapping up younger rivals.</p>
<p class="css-at9mc1 evys1bk0">Still, legal experts cautioned that it might be challenging for the F.T.C. to win. That’s because the government must prove something unknowable: that Meta, formerly known as Facebook, wouldn’t have achieved the same success without the acquisitions. It is also extremely rare to try to unwind mergers approved years ago, legal experts said.</p>
<p class="css-at9mc1 evys1bk0">“One of the most difficult things for antitrust laws to deal with is when industry leaders purchase small potential competitors,” said Gene Kimmelman, a former senior official in the Obama administration’s Department of Justice. Meta, he added, “bought many things that either didn’t pan out or were integrated. How are Instagram and WhatsApp different?”</p>
<p>The efforts continue a yearslong bipartisan pursuit to curtail the vast power that a handful of tech companies have over commerce, the exchange of ideas, entertainment and political discourse. Despite attempts by tech executives to court President Trump, his antitrust appointees have signaled that they will continue the course.</p>
<p class="css-at9mc1 evys1bk0">The F.T.C.’s case against Meta is the third major tech antitrust lawsuit to go to trial in the past two years. Last year, the D.O.J. won its antitrust case against Google for monopolizing internet search. A federal judge is set to hear arguments over remedies, including a potential breakup, next week. The D.O.J. also completed a separate trial against Google for monopolizing ad technology, which is still being decided by a federal judge.</p>
<p class="css-at9mc1 evys1bk0">The Justice Department has also sued Apple, and the F.T.C. has sued Amazon, accusing the companies of antitrust violations. Those trials are expected to begin next year.</p>
<p class="css-at9mc1 evys1bk0">The case against Meta could affect its 3.5 billion users, who on average log onto Facebook, Instagram or WhatsApp multiple times a day for news, shopping and texting. Instagram and WhatsApp have attracted more users in recent years as Facebook, Meta’s flagship app, has stopped growing.</p>
<p class="css-at9mc1 evys1bk0">F.T.C. Chairman Andrew Ferguson was in the courtroom to listen to the government’s opening statement. Meta’s chief legal officer, Jennifer Newstead, and Joel Kaplan, its chief global affairs officer, also attended. Alex Schultz, Meta’s chief marketing officer, sat at the litigator’s table and will serve as the company’s executive at the trial.</p>
<p class="css-at9mc1 evys1bk0">Presiding over the case is Judge James Boasberg, 62, the senior judge in the federal court. He is already in the national spotlight for rejecting the Trump administration’s effort to use a powerful wartime statute to summarily deport Venezuelan migrants it deemed to be members of a violent street gang.</p>
<p class="css-at9mc1 evys1bk0">Judge Boasberg has said he had never been a user of Meta’s apps, but was familiar with Facebook Live, which has been featured in criminal trials. He took notes as Mr. Matheson explained the government’s definitions of social networking and methodology to determine Meta was a monopoly. He was equally focused on Meta’s rebuttal of those definitions.</p>
<p class="css-at9mc1 evys1bk0">The F.T.C. argued that Mr. Zuckerberg said in 2006 that Facebook was used to connect “actual friends.” The F.T.C. has argued that Meta has had a monopoly in social networking since 2011 and that SnapChat was among the only comparable platforms to Facebook and Instagram.</p>
<p class="css-at9mc1 evys1bk0">Meta rejected the F.T.C.’s definition of social networking, saying it faces competition from TikTok, LinkedIn, YouTube and other platforms. Mr. Hansen said it competed with messaging apps for sharing content between friends and family.</p>
<p class="css-at9mc1 evys1bk0">He said more than half of all engagement on Facebook and Instagram is of videos, which put Meta squarely in competition with TikTok, the fast-growing short-video app. When TikTok was momentarily shut down in January, Meta saw a surge of usage to Facebook, Instagram and YouTube, which shows the company has plenty of competition.</p>
<p class="css-at9mc1 evys1bk0">“Meta has no monopoly,” Mr. Hansen said.</p>
<p class="css-at9mc1 evys1bk0">During what is projected to be an eight-week trial, the government and Meta are expected to tell competing versions of the company’s 20-year growth story.</p>
<p class="css-at9mc1 evys1bk0">The F.T.C.’s argument hinges on Section 2 of the Sherman Antitrust Act of 1890, which forbids a company from maintaining a monopoly through anticompetitive practices.</p>
<p class="css-at9mc1 evys1bk0">The F.T.C. accused Facebook, as the company was previously known, of struggling to build a mobile app and fearing that Instagram would rapidly outpace it in popularity. The company overpaid when it purchased Instagram in 2012 for $1 billion, the F.T.C. argued.</p>
<p class="css-at9mc1 evys1bk0">In 2014, as WhatsApp grew, Meta offered to buy the company for $19 billion — also far above its market value, the government said.</p>
<p class="css-at9mc1 evys1bk0">The F.T.C. plans to highlight a paper trial of emails between Meta executives, alongside other evidence, to argue that the company bought the start-ups because they were threats.</p>
<p class="css-at9mc1 evys1bk0">In his opening remarks, Mr. Matheson mentioned documents, including what he described as a “smoking gun” February 2012 email by Mr. Zuckerberg, in which the chief executive discussed the rise of Instagram and the importance of “neutralizing a potential competitor.” In another email in November 2012 to the former chief operating officer, Sheryl Sandberg, Mr. Zuckerberg wrote, “Messenger isn’t beating WhatsApp, Instagram was growing so much faster than us that we had to buy them for $1 billion.”</p>
<p class="css-at9mc1 evys1bk0">The F.T.C. lawyer said Meta bought WhatsApp to keep it from being acquired by competitors like Google, which were trying to use a messaging service to launch a competing social network. Meta’s acquisition of WhatsApp was intended to build a “moat” around the company’s monopoly in social networking, Mr. Matheson said.</p>
<p class="css-at9mc1 evys1bk0">The government is set to call witnesses from Meta, as well as competitors, venture capitalists, economists and media industry executives. Mr. Zuckerberg was expected to be called as the first witness as soon as Monday. The F.T.C. said Ms. Sandberg, and Kevin Systrom, co-founder of Instagram, would testify this week.</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/metas-antitrust-trial-begins-as-ftc-argues-company-built-social-media-monopoly/">Meta’s Antitrust Trial Begins as FTC Argues Company Built Social Media Monopoly</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/metas-antitrust-trial-begins-as-ftc-argues-company-built-social-media-monopoly/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Eli Lilly to release weight loss pill orforglipron trial data</title>
		<link>https://www.ourstoryinsight.com/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data/</link>
					<comments>https://www.ourstoryinsight.com/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Tue, 25 Mar 2025 10:15:59 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Eli]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[orforglipron]]></category>
		<category><![CDATA[pill]]></category>
		<category><![CDATA[Release]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[weight]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=6044</guid>

					<description><![CDATA[<p>A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson &#124; Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Eli Lilly plans to [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data/">Eli Lilly to release weight loss pill orforglipron trial data</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="HighlightShare-hidden" style="top:0;left:0"/></p>
<p>A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.</p>
<p>Scott Olson | Getty Images</p>
<p>Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market.</p>
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-2">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The company has said it expects to unveil data from five studies in patients with Type 2 diabetes and two trials in people with obesity in 2025. </p>
<p>Analysts expect the pill to be as effective, safe and tolerable to take as <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-5">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span>&#8216;s semaglutide – the active ingredient in its popular but costly weight loss injection Wegovy and diabetes drug Ozempic. The trial results are among the pharmaceutical industry&#8217;s most critical and closely watched of the year, as they bring Eli Lilly&#8217;s drug one step closer to becoming a new, needle-free alternative for weight loss and diabetes. </p>
<p>&#8220;This could join a growing toolbox of medications for obesity, and it could be a game-changer,&#8221; said Dr. Eduardo Grunvald, medical director for UC San Diego&#8217;s Center for Advanced Weight Management.</p>
<p>If it enters the market, orforglipron could help more patients access the treatments and alleviate the supply shortfalls of<strong> </strong>the injections on the market.<strong> </strong>The pill could also help Eli Lilly solidify its dominance in the growing segment as a slate of other drugmakers race to bring a product to the market.</p>
<p>Offering the first oral version of a so-called GLP-1<strong> </strong>could help Eli Lilly capture an even greater share of the market for that popular class of weight loss and diabetes drugs. Eli Lilly is currently about three years ahead of other drugmakers developing pills, including <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-6">Pfizer<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span>, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-7">AstraZeneca<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span>, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-8">Roche<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span>, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-9">Structure Therapeutics<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> and <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-10">Viking Therapeutics<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span>, Guggenheim analyst Seamus Fernandez told CNBC.</p>
<p>Some analysts expect the market for GLP-1s to be worth more than $150 billion annually by the early 2030s. Oral GLP-1s could grow to be worth $50 billion of that total, Fernandez said. </p>
<p>In a statement, Eli Lilly said it is &#8220;investigating orforglipron for the potential to bring a safe and effective treatment to people with these diseases who are looking for a convenient, oral option.&#8221;</p>
<p>Eli Lilly&#8217;s pill works in a similar way to Wegovy, Ozempic, and Novo Nordisk&#8217;s diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person&#8217;s appetite and regulate blood sugar. </p>
<p>But unlike those three medications, Eli Lilly&#8217;s pill is not a peptide medication. That means it is absorbed more easily in the body and doesn&#8217;t require dietary restrictions like Rybelsus does. </p>
<p>It is unclear whether orforglipron will have a hefty list price similar to those of the injections, which cost roughly $1,000 per month, or whether it will help expand insurance coverage for obesity treatments. Medicare and many employer-based plans still don&#8217;t cover those drugs. But so-called small molecule pills will at least be easier for Eli Lilly to manufacture than injections. </p>
<p>In January, Eli Lilly CEO Dave Ricks said the pill could receive U.S. regulatory approval as soon as early 2026. The company also said in its annual report in February it recorded a nearly $550 million &#8220;pre-launch inventory&#8221; charge for oforglipron, meaning it is preparing to manufacture the drug even before its approval. </p>
<p>&#8220;That&#8217;s a good indicator that they are comfortable with what they&#8217;re seeing across the trials,&#8221; BMO Capital Markets analyst Evan Seigerman told CNBC.</p>
<p>Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro –  which targets GLP-1 but also activates another gut hormone called GIP.</p>
<p>Fueled by those treatments, Eli Lilly has become the largest global pharmaceutical and health-care company by market cap, with a market value of about $814 billion as of Monday. The company raked in more than $45 billion in revenue in 2024 alone, a significant share of which came from its portfolio of diabetes and obesity products.</p>
<h2 class="ArticleBody-subtitle">Who could benefit from the pill</h2>
<p>While injections will likely remain a popular option, a once-daily pill like Eli Lilly&#8217;s could be much easier for some patients to take and store. </p>
<p>&#8220;What we&#8217;re going to see over the next couple of years is that we&#8217;re moving away from one-size-fits-all products to more customized products that are more directly aligned to the profile of the patient,&#8221; Seigerman said.</p>
<p>Patients can inject Zepbound and Wegovy under their skin with a click of a button, but must follow specific instructions, such as storing the shots at certain temperatures and injecting in a different spot each week. Meanwhile, Rybelsus must be taken in the morning on an empty stomach with no more than four ounces of plain water.</p>
<p>Rebekah Carl injects herself with her weekly dose of Wegovy in New Columbia, Pennsylvania, U.S., November 13, 2023.</p>
<p>Hannah Beier | Reuters</p>
<p>Orforglipron does not have dietary restrictions, and will also offer an option for patients who could benefit from treatment but are afraid of needles. </p>
<p>Th pill could also tap into new markets in countries that don&#8217;t have the resources for the cold supply chains needed to store and administer GLP-1 injections, Guggenheim&#8217;s Fernandez said.</p>
<p>People who lost weight on the injections and are tired of taking a shot every week could also be &#8220;good candidates&#8221; to switch to a pill and take them as maintenance doses, which are meant to be taken long term to prolong the effects of a drug, Seigerman added. Eli Lilly is studying orforglipron as a maintenance dose in patients who took tirzepatide throughout a phase three trial called SURMOUNT-5, with results expected in early 2026. </p>
<p>Still, some patients who don&#8217;t mind taking injections may continue their current treatment regimen, UCSD&#8217;s Grunvald noted. He said some people already take several pills for other conditions each day, so they may prefer to take an injection once a week &#8220;and forget about it rather than adding another pill.&#8221;</p>
<p>Eli Lilly&#8217;s pill could also be more fit for people who are overweight or &#8220;modestly obese,&#8221; said Leerink Partners analyst David Risinger. Those who have a very high body mass index will &#8220;best be treated with injectables that offer greater efficacy,&#8221; Risinger said.</p>
<p>While orforglipron is expected to be as good for weight loss as Wegovy, Zepbound, on average, is more effective at helping patients lose weight than Novo Nordisk&#8217;s injection, according to real-world data and a head-to-head trial on the drugs.</p>
<p><strong>Late-stage diabetes trials on orforglipron</strong></p>
<ul>
<li><strong>ACHIEVE-1 – </strong>Study of orforglipron in adults with Type 2 diabetes and inadequate control of blood sugar levels with diet and exercise </li>
<li><strong>ACHIEVE-5 –</strong> Study of orforglipron in patients with Type 2 diabetes and inadequate control of blood sugar levels with insulin glargine, with or without the diabetes treatments Metformin and/or SGLT-2 Inhibitors</li>
<li><strong>ACHIEVE-J – </strong>Long-term safety study of orforglipron in patients with Type 2 diabetes</li>
<li><strong>ACHIEVE-3 – </strong>Study of orforglipron compared with semaglutide in participants with Type 2 diabetes inadequately controlled with Metformin</li>
<li><strong>ACHIEVE-4 – </strong>Study of orforglipron compared with insulin glargine in patients with Type 2 diabetes and obesity or overweight at increased cardiovascular risk</li>
<li><strong>ACHIEVE-2 – </strong>Study of orforglipron compared with dapagliflozin (prescription drug for diabetes and heart failure) in patients with Type 2 diabetes and inadequate control of blood sugar levels with Metformin</li>
</ul>
<p>A pill is a welcome alternative for patients like Willow Baillies, 29, who has been injecting herself with cheaper, compounded versions of Zepbound because her insurance does not cover the branded medication. </p>
<p>The Food and Drug Administration, in most cases, now bars compounding pharmacies from making those unapproved versions because it declared the Zepbound shortage over in December. </p>
<p>Baillies, a human resources specialist based in Milwaukee, Wisconsin, said a pill would &#8220;offer peace of mind because I don&#8217;t have to think much about taking it.&#8221; Currently, her injections require careful preparation, such as disinfecting her entire counter with alcohol pads. </p>
<p>Orforglipron&#8217;s entrance into the market could also help the weight loss drug market reach more patients in the primary care setting who are not currently receiving treatment but could benefit from it, Seigerman said. While some primary care doctors can and do prescribe GLP-1s, others are hesitant due to concerns about side effects and administration since they are injections.  </p>
<p>He said the primary care part of the market is key for the weight loss drug market to hit Wall Street&#8217;s lofty forecasts.</p>
<h2 class="ArticleBody-subtitle">Accessibility, pricing and insurance </h2>
<p>Still, Seigerman said he believes primary care providers who prescribe pills may still encounter issues with pricing and insurance coverage.</p>
<p>He said he doesn&#8217;t expect orforglipron to cost significantly less than existing injections because pharmaceutical products are &#8220;typically priced by the value that they bring, regardless of the route of administration.&#8221; For example, Rybelsus costs about $997 a month before insurance, the same list price as Ozempic. </p>
<p>Risinger said he expects orforglipron to be priced at a slight discount to Zepbound, which means Eli Lilly&#8217;s pill could cost significantly less than Wegovy. </p>
<p>The list price of Wegovy – nearly $1,350 per month – is already around a 20% premium to Zepbound&#8217;s list price of just under $1,100 per month, he said. That means if the pill costs 10% to 15% less than Zepbound, it would be almost a 30% to 35% discount compared to Wegovy, according to Risinger. </p>
<p>But Risinger said he does not necessarily expect the pill to lead to better insurance coverage for obesity medications. He believes orforglipron will be covered by some plans like Zepbound is, but certain employers will likely still fear that some patients are only using obesity drugs for cosmetic purposes. Other employers are still balking at the high costs associated with covering those treatments. </p>
<p>Jill Skala, a teacher in western Pennsylvania, said she would &#8220;definitely consider&#8221; taking a pill if it was less expensive than Zepbound and had &#8220;equal efficacy or better.&#8221; Skala, 49 is currently taking Zepbound and also has a nine-month supply of compounded tirzepatide, which she expects to use until the end of the year. </p>
<p>&#8220;I would probably just stay with Zepbound if [the pill] wasn&#8217;t significantly less expensive, as long as Zepbound was still working for me,&#8221; Skala told CNBC.</p>
<h2 class="ArticleBody-subtitle">Trial data expectations </h2>
<p>Fotografiabasica | E+ | Getty Images</p>
<p>Several analysts said they expect Eli Lilly&#8217;s pill to be as effective or slightly less than injectable semaglutide, the active ingredient in Ozempic and Wegovy, in phase three trials. </p>
<p>In patients with obesity, that implies weight loss of around 13% to 15%, according to a February note from JPMorgan analyst Chris Schott. That is in line with or slightly below Wegovy&#8217;s 15% average weight loss in phase three trials.</p>
<p>Eli Lilly&#8217;s phase two trial examined different doses of the pill in overweight or obese patients, with a highest dose of 45 milligrams. But the company is only giving doses of up to 36 milligrams in phase three trials on orforglipron. </p>
<p>Overweight or obese patients who took 36 milligrams of the pill once a day lost 13.5% of their body weight on average after 36 weeks in Eli Lilly&#8217;s phase two trial. That compares with an average weight loss of 2.3% for people who received a placebo.</p>
<p>Eli Lilly expects weight loss in people with diabetes to be &#8220;significantly less&#8221; than patients with obesity who don&#8217;t have diabetes, the company&#8217;s Chief Scientific Officer Daniel Skovronsky said on an earnings call in February. That&#8217;s based on prior studies on orforglipron and other GLP-1 therapies, he noted. </p>
<p>Schott said weight loss among diabetes patients could come in between 6% to 8%. He also expects hemoglobin A1c – a blood test that measures the average blood sugar level over the past two to three months – to improve by 1.8 to 2.1 points. That would be in line with results seen in diabetes patients who took Ozempic. </p>
<p>In a phase two trial, orforglipron led to an HbA1c reduction of up to 2.1% at 26 weeks in adults with diabetes, compared to a decrease of 0.4% among those who took a placebo. </p>
<p><strong>Late-stage obesity trials, other studies on orforglipron</strong></p>
<ul>
<li><strong>ATTAIN-J</strong> – Study of orforglipron in Japanese adults with obesity </li>
<li><strong>ATTAIN-1</strong> – Study of orforglipron in adults who have obesity or are overweight with weight-related comorbidities </li>
<li><strong>ATTAIN-2</strong> – Study of orforglipron in adults who have obesity or are overweight and have Type 2 diabetes</li>
<li><strong>ATTAIN-MAINTAIN</strong> – Study of orforglipron for the maintenance of body weight loss in patients who have obesity or are overweight with weight-related comorbidities </li>
<li><strong>ATTAIN-OSA</strong> – Study of orforglipron in people with obstructive sleep apnea and who have obesity or are overweight</li>
</ul>
<p>However, how well patients tolerate Eli Lilly&#8217;s pill – specifically the rate of gastrointestinal side effects in the trial – will be the &#8220;key focus&#8221; of the phase three study results, according to Schott. It&#8217;s an issue top of mind for doctors, patients and investors because side effects such as nausea and vomiting are a significant reason why some people stop taking the injections.</p>
<p>Schott said the bar for orforglipron is nausea rates of less than 25% and vomiting rates in the low double digits for diabetes patients. </p>
<p>He expects orforglipron to cause slightly worse rates of gastrointestinal side effects in patients with obesity. That could lead to &#8220;tolerability worse than Zepbound but closer to Wegovy,&#8221; Schott added.</p>
<p>Orforglipron&#8217;s nausea and vomiting rates in the phase two trial were &#8220;meaningfully greater&#8221; than those among patients who took 2-milligram doses of semaglutide in a phase three trial, Leerink&#8217;s Risinger said. </p>
<p>But he expects patients to tolerate Eli Lilly&#8217;s pill better in phase three trials because they are longer in duration than the mid-stage studies and likely involve slower titration. That refers to how quickly patients start at a lower dose of a drug and ramp up to a higher target dose. </p>
<p>On safety, Schott said he expects a &#8220;very low probability&#8221; of any issues that could put the entire development program for orforglipron at risk. He also believes it is highly unlikely that there will be any concerns related to liver toxicity – an issue that derailed one of Pfizer&#8217;s experimental obesity pills. </p>
<h2 class="ArticleBody-subtitle">What the pill means for competitors</h2>
<p>Positive data on the pill and a potential approval would be a boon to Eli Lilly, but could also be good news for other companies developing oral GLP-1s, according to some analysts. </p>
<p>Orforglipron&#8217;s success could &#8220;validate&#8221; that administering a GLP-1 orally is possible, BMO&#8217;s Seigerman said. </p>
<p><strong>Other drugmakers developing obesity pills</strong></p>
<p>But Seigerman said it will also put pressure on smaller companies developing pills, such as Structure Therapeutics, to find a partner that can help them compete in the weight loss drug market with pharmaceutical behemoths like Eli Lilly. </p>
<p>Guggenheim&#8217;s Fernandez said disappointing data or any safety issues that come up with Eli Lilly&#8217;s pill will &#8220;raise the bar that investors are considering&#8221; for non-peptide oral GLP-1s. Poor results could negatively impact the perception of those drugs, he added.</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data/">Eli Lilly to release weight loss pill orforglipron trial data</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Merck says experimental RSV treatment protected infants in trial</title>
		<link>https://www.ourstoryinsight.com/merck-says-experimental-rsv-treatment-protected-infants-in-trial/</link>
					<comments>https://www.ourstoryinsight.com/merck-says-experimental-rsv-treatment-protected-infants-in-trial/#respond</comments>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Fri, 18 Oct 2024 04:47:23 +0000</pubDate>
				<category><![CDATA[Business]]></category>
		<category><![CDATA[experimental]]></category>
		<category><![CDATA[infants]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[protected]]></category>
		<category><![CDATA[RSV]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Trial]]></category>
		<guid isPermaLink="false">https://www.ourstoryinsight.com/?p=3516</guid>

					<description><![CDATA[<p>The logo for Merck is displayed on a screen at the New York Stock Exchange on Nov. 17, 2021. Andrew Kelly &#124; Reuters Merck on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step closer to filing [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/merck-says-experimental-rsv-treatment-protected-infants-in-trial/">Merck says experimental RSV treatment protected infants in trial</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="HighlightShare-hidden" style="top:0;left:0"/></p>
<p>The logo for Merck is displayed on a screen at the New York Stock Exchange on Nov. 17, 2021.</p>
<p>Andrew Kelly | Reuters</p>
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Merck<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step closer to filing for approval of the shot. </p>
<p>The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV, which causes thousands of deaths among older Americans and hundreds of deaths among infants each year. Complications from the virus are the leading cause of hospitalization among newborns, making Merck&#8217;s drug a valuable new treatment option if approved.</p>
<p>Merck plans to discuss the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season, according to a release. </p>
<p>The trial examined the safety and efficacy of a single dose of the treatment, clesrovimab, in healthy preterm and full-term infants entering their first RSV season. Merck presented the results at the medical conference IDWeek in Los Angeles.</p>
<p>The treatment reduced RSV-related hospitalizations by more than 84% and decreased hospitalizations due to lower respiratory infections by 90% compared with a placebo among infants through five months, according to Merck. Clesrovimab also reduced lower respiratory infections that required medical attention by more than 60% compared with a placebo through five months.</p>
<p>RSV is a common cause of lower respiratory tract infections such as pneumonia. Results were consistent through both the five-month and six-month time points in the trial, Merck said.</p>
<p>The rates of adverse and serious side effects were comparable between patients who received Merck&#8217;s shot and those who took placebos in the trial. There were no treatment or RSV-related deaths in the study, the company added. </p>
<p>&#8220;These promising results demonstrating decreased incidence of RSV disease, including hospitalizations, highlight the potential for clesrovimab to play an important role in helping to alleviate the continued burden of RSV on infants and their families,&#8221; Dr. Octavio Ramilo, chair of the Department of Infectious Diseases at St. Jude&#8217;s Children&#8217;s Research Hospital, said in Merck&#8217;s release. Ramilo is also an investigator working on the trials. </p>
<p>Merck&#8217;s clesrovimab could potentially compete against a similar treatment from <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-6">Sanofi<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> and <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-7">AstraZeneca<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> called Beyfortus, which was in short supply nationwide last RSV season due to unprecedented demand. Both are monoclonal antibodies, which deliver antibodies directly into the bloodstream to provide immediate protection. </p>
<p>But Merck&#8217;s treatment can be administered to infants regardless of their weight, which the company said may offer convenience in terms of dosing. Meanwhile, the recommended dosage of Beyfortus is based on an infant&#8217;s body weight. </p>
<p>Last year, <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-8">Pfizer<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> and <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-9">GSK<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><span class="AddToWatchlistButton-addWatchListFromTag"/></span></span></span> rolled out RSV vaccines that are administered to expectant mothers who can pass on protection to their fetuses. </p>
<p>The post <a rel="nofollow" href="https://www.ourstoryinsight.com/merck-says-experimental-rsv-treatment-protected-infants-in-trial/">Merck says experimental RSV treatment protected infants in trial</a> appeared first on <a rel="nofollow" href="https://www.ourstoryinsight.com">Our Story Insight</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.ourstoryinsight.com/merck-says-experimental-rsv-treatment-protected-infants-in-trial/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
